Presidio gets exclusive rights to XTL's HCV compounds
XTL Biopharmaceuticals (focused on neurological and infectious diseases) licensed Presidio Pharmaceuticals (antivirals) exclusive development and commercialization rights to preclinical hepatitis C compounds targeting NS5A.
- Large Molecule
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com